SCHEMBL7986753

SCHEMBL7986753

O=c1[nH]c(-c2ccc(F)cc2)nc2ncn(Cc3ccccc3F)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 3/20 0.43
TNKS2 Q9H2K2 3/20 0.43
PARP2 Q9UGN5 2/20 0.43
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 3/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
ROCK2 O75116 1/20 0.40
MEN1 O00255 2/20 0.40
HPGD P15428 1/20 0.39
CYP1A1 P04798 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP1B1 Q16678 1/20 0.39
PARP1 P09874 1/20 0.38
ACP1 P24666 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7987219 0.93 ALDH1A1 (0.45) LMNATP53POLBALDH1A1SMN1; SMN2
SCHEMBL7991414 0.90 GRIA1 (0.42) LMNATP53POLBALDH1A1SMN1; SMN2
SCHEMBL7988742 0.88 LMNA (0.42) LMNATP53POLBALDH1A1SMN1; SMN2
SCHEMBL7973916 0.86 LMNA (0.43) LMNATP53POLBALDH1A1SMN1; SMN2
SCHEMBL7974505 0.86 SMN1; SMN2 (0.55) TNKSTNKS2PARP2LMNAALDH1A1
SCHEMBL7985420 0.85 TP53 (0.42) LMNATP53POLBALDH1A1SMN1; SMN2
SCHEMBL7985116 0.85 HPGD (0.44) LMNATP53POLBALDH1A1SMN1; SMN2
SCHEMBL7984279 0.85 SMN1; SMN2 (0.47) TNKSTNKS2PARP2ALDH1A1SMN1; SMN2
SCHEMBL7974198 0.84 LMNA (0.41) LMNATP53POLBALDH1A1SMN1; SMN2
SCHEMBL7984677 0.84 TP53 (0.41) LMNATP53POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6310070-B1 FOR TREATING NEPHRITIS, IMPROVING PROTEINURIA DUE TO GLOMERULONEPHRITIS AND PREVENTING AGGRAVATION OF NEPHRITIS JAPAN ENERGY CORPORATION (JP) 2001-10-30 US disclosed
EP-0999211-A1 NOVEL PURINE DERIVATIVES AND MEDICINAL USE THEREOF JAPAN ENERGY CORPORATION (JP) 2000-05-10 EP disclosed